Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505

Published on 05/14/2024 at 05:30 - Modified on 05/14/2024 at 05:31

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Dr. Lal PathLabs Limited

Dr. Lal PathLabs Expands Genomics Capabilities with New Sequencing System	Jun. 25	MT
Nomura Adjusts Dr. Lal PathLabs' Price Target to INR3,560 From INR3,315, Keeps at Buy	Apr. 28	MT
Dr. Lal PathLabs Limited, Q4 2025 Earnings Call, Apr 25, 2025	Apr. 25
India's Dr Lal Path Labs beats quarterly profit view on medical testing boom	Apr. 25	RE
Dr. Lal PathLabs Limited Reports Earnings Results for the Full Year Ended March 31, 2025	Apr. 25	CI
Dr. Lal PathLabs Launches South Asia's First Test for Amyloid Protein Typing	Apr. 15	MT
Dr. Lal Pathlabs Launches Advanced Test For Amyloidosis	Apr. 15	RE
Dr. Lal Pathlabs Limited Launches Advanced Test for Amyloidosis	Apr. 15	CI
Dr. Lal PathLabs Arm Gets Members' Nod for Voluntary Liquidation	Feb. 06	MT
Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR3,315 From INR3,310	Jan. 31	MT
Dr. Lal PathLabs Limited, Q3 2025 Earnings Call, Jan 30, 2025	Jan. 30
India's Dr Lal Path Labs posts higher Q3 profit on steady testing demand	Jan. 30	RE
Dr. Lal PathLabs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	Jan. 30	CI
Antara Partners with Dr. Lal Pathlabs to Strengthen Its Geriatric Care Services	Dec. 19	CI
Nomura Downgrades Dr. Lal PathLabs to Neutral From Buy, Adjusts Price Target to INR3,310 From INR3,720	24-10-25	MT
Dr. Lal PathLabs Limited, Q2 2025 Earnings Call, Oct 23, 2024	24-10-23
India's Dr Lal Path Labs posts bigger-than-expected Q2 profit on demand for medical tests	24-10-23	RE
Dr. Lal Pathlabs Limited Announces Stepping Down of Dr. Om Prakash Manchanda as Managing Director, Effective March 31, 2025	24-10-23	CI
Dr. Lal PathLabs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	24-10-23	CI
Nomura Adjusts Dr. Lal PathLabs' Price Target to INR3,720 From INR2,713, Keeps at Buy	24-08-12	MT
Dr. Lal PathLabs Limited, Q1 2025 Earnings Call, Aug 07, 2024	24-08-07
India's Dr Lal PathLabs tops Q1 profit estimates on strong testing demand	24-08-07	RE
Dr. Lal PathLabs Limited Reports Earnings Results for the First Quarter Ended June 30, 2024	24-08-07	CI
Nomura Upgrades Dr. Lal Pathlabs to Buy From Neutral, Adjusts Price Target to INR2,713 From INR2,505	24-05-14	MT
Dr. Lal PathLabs Limited, Q4 2024 Earnings Call, May 10, 2024	24-05-10

DR. LAL PATHLABS LIMITED

Stock

LALPATHLAB

INE600L01024

Delayed NSE India S.E. Other stock markets 06:24:41 2025-07-17 am EDT
2,982.30 ^INR	-0.11%

More quotes

Chart

Duration

Period

LALPATHLAB: Dynamic Chart

Income Statement and Estimates

More financial data

Headlines

Results preview: Legrand accelerates

Crypto companies face the fatal trap of Bitcoin - Crypto roundup

July 17, 2025 at 05:24 am EDT

When volatility boosts US banks

July 17, 2025 at 04:42 am EDT

Shorting the dollar: the most popular trade amongst fund managers

July 17, 2025 at 03:20 am EDT

The Week's Biggest Mergers Unpacked

July 16, 2025 at 10:12 am EDT

Diageo reshuffles its management team: Nik Jhangiani temporarily replaces Debra Crew

July 16, 2025 at 09:29 am EDT

How did Indonesia go from 32% to 19% customs tariffs?

July 16, 2025 at 09:23 am EDT

Rare earths: Apple joins the industrial front supported by the Pentagon

July 16, 2025 at 06:16 am EDT

Is Scott Bessent the ideal candidate to succeed Jerome Powell?

July 16, 2025 at 06:06 am EDT

Rio Tinto posts strongest iron ore output since 2018 amid executive shake-up

July 16, 2025 at 04:08 am EDT

All our articles